EVerZom joins the consortium of the INSPIRE program, a 12.8 million euro project on lung cancer funded by Horizon Europe.
The INSPIRE project aims to make a significant and tangible impact on the European cancer plan and the EU cancer mission.
It brings together European partners spanning biotechnology, medical devices, cancer research, academia and patient advocacy, including Aerogen Limited (Ireland), Trinity College Dublin (Ireland), RemedyBio (Ireland), Myriad Associates (Ireland), EVerZom (France), Biopharma Excellence (Pharmalex) (Germany), Deutsches Krebsforschungszentrum (DKFZ) (Germany), and Lung Cancer Europe (Switzerland).
This world-class consortium will advance the development of regenerative gene therapy as a transformative new treatment for lung cancer.
EVerZom, an Erganeo start-up, is developing an innovative process for the production of extracellular vesicles (EVs).